The feud between Arcellx and Legend Biotech over their anti-BCMA CAR-T therapies for multiple myeloma is getting extra spicy ...

Treatment with subcutaneous daratumumab significantly improved progression-free survival in patients with intermediate- or high-risk smoldering multiple myeloma.

An expanded analysis from the phase 3 CEPHEUS trial showed that daratumumab plus VRd improved MRD responses as well as ...

Black women experience advanced diagnoses 55% more often than white women and are more likely to die from the disease, the ...

These long-term data support axicabtagene ciloleucel as a highly effective therapeutic approach for patients with relapsed or ...

PM8002/BNT327 plus nab-paclitaxel demonstrated “clinically meaningful” activity in advanced TNBC, according to researchers.

As part of the imPACT Review mission, hospitals and health facilities providing cancer care around the country were visited to assess existing oncology capacities and infrastructure. Here, Arun Banu ...

The rates of late-stage breast cancer at diagnosis have risen among women in all racial and ethnic groups, but Black women ...

GSK's Blenrep combo demonstrates significant survival benefits and improved efficacy in relapsed multiple myeloma compared to ...

Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic ...

Pirtobrutinib, a third-generation BTK inhibitor, showed superior progression-free survival and lower treatment ...

Mansi Shah, MD, assistant professor, Rutgers Cancer Institute of New Jersey, shares long-term follow-up data on the efficacy ...